Editors’ Picks: January Highlights from AACR Journals
To kick off the new year, the editors of the 10 AACR journals highlighted two phase I clinical trials,...
Progress Against Cancer
To kick off the new year, the editors of the 10 AACR journals highlighted two phase I clinical trials,...
Guest post by Hisham Hamadeh, PhD, and Shawn M. Sweeney, PhD Imagine a world where many of the decisions...
Therapeutic antibodies carry ‘payloads’ to destroy cancer cells.
Neurologist David Schiff discusses the significance of new evidence-based guidance on how to treat brain metastases from solid tumors.
Cardiovascular mortality rates for survivors of early-stage Hodgkin lymphoma outpace cancer-related mortality.
Technology could help detect lymphedema earlier.
Scientists look to decode the role of intestinal bacteria in our responses to immunotherapy.
Cancer treatment is a double-edged sword. Intense or multi-pronged treatment may lead to better killing of tumor cells, but...
The new AKT inhibitor doubled progression-free survival when added to treatment with Faslodex.
Study finds pausing endocrine therapy is safe for early-stage breast cancer patients eager to expand their families.